CCL17 and neoplasm: These studies have reported the downregulation of the frequency of intratumor myeloid-derived suppressor cells (MDSCs) and increased CTL activity in response to high doses of LXR agonists [56], and the reduction of intratumoral regulatory T cells (Treg) depending on the downregulation of the Treg-attracting chemokine Ccl17 by MHC-IIhigh tumor-associated macrophages in response to lower doses of LXR agonists [57].